NeuroVia

About NeuroVia

Neurovia Bioelectronics, a spin-off from the École Polytechnique Fédérale de Lausanne (EPFL) headquartered in Geneva, Switzerland, was established in 2024. The company operates within the therapeutic devices and medtech sector, concentrating on developing bioelectronic systems that interface human physiology with artificial intelligence. The founding team consists of Dr. William Esposito, who was a postdoc at EPFL, and Omar Shalby, an EPFL Neuro-X master's student. Their collective background is rooted in material science, microfabrication, and soft neural interfaces, which forms the scientific foundation of the company.

The company is addressing health conditions such as drug-resistant hypertension and postural hypotension, for which effective solutions are currently lacking. Neurovia Bioelectronics is engineering a neural interface delivered through a minimally invasive and reversible stent that targets renal nerves to modulate blood pressure. This procedure is designed to last less than an hour. Unlike existing renal denervation (RDN) methods that often involve ablation or "burning" of the nerves, Neurovia's technology is designed to communicate with and modulate nerve behavior without causing destruction. This approach creates a platform technology that can sense, adapt, and potentially be applied to other conditions beyond hypertension, such as heart failure and multi-organ control.

Neurovia's business model centers on creating these advanced implants as a category-defining solution in the bioelectronics and cardiovascular medtech space. The company serves patients, particularly the elderly and those with autonomic dysfunctions, who suffer from conditions like postural hypotension. Since its inception, Neurovia Bioelectronics has been active in the startup ecosystem, participating in the first batch of the HSG START Accelerator program in late 2025 and securing an award from Venture Kick the same year. It has received initial funding from various accelerators including HSG START, EPFL, Venture Kick, and Fongit.